Indication

Dystrophic epidermolysis bullosa

Dystrophic epidermolysis bullosa is a rare inherited genodermatosis characterized by extreme mechanical fragility of the skin and mucous membranes, with clinical onset typically occurring at birth or during early infancy. Read more about Dystrophic epidermolysis bullosa

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Dystrophic epidermolysis bullosa therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Dystrophic epidermolysis bullosa preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Dystrophic epidermolysis bullosa.

Dystrophic epidermolysis bullosa is a rare inherited genodermatosis characterized by extreme mechanical fragility of the skin and mucous membranes, with clinical onset typically occurring at birth or during early infancy.

Pathophysiologically, the disorder is caused by mutations in the *COL7A1* gene, which leads to a deficiency or defect in type VII collagen, the primary component of anchoring fibrils that secure the epidermal basement membrane to the underlying dermis.

Blistering develops in the sub-lamina densa plane in response to minor friction or trauma, resulting in chronic non-healing erosions, extensive scarring, nail dystrophy, pseudosyndactyly (mitten deformities), and esophageal strictures.

Severe forms, particularly recessive subtypes, are further complicated by chronic systemic inflammation, growth impairment, and a markedly elevated lifetime risk of aggressive cutaneous squamous cell carcinoma.

Personalize your experience

Follow Dystrophic epidermolysis bullosa and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it